Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MUK nine b: OPTIMUM. A phase II study evaluating multiple novel agentsoptimised combination of biological therapy in newly diagnosed high risk multiple myeloma and plasma cell leukaemia

Next Previous
X
Search
Trial Profile

MUK nine b: OPTIMUM. A phase II study evaluating multiple novel agentsoptimised combination of biological therapy in newly diagnosed high risk multiple myeloma and plasma cell leukaemia

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 17 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bortezomib (Primary) ; Daratumumab (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary) ; Cyclophosphamide; Filgrastim; Melphalan
  • Indications Multiple myeloma; Plasma cell leukaemia
  • Focus Therapeutic Use
  • Acronyms MUKnineb; OPTIMUM; UK OPTIMUM

    • Most Recent Events

    • 13 May 2024 Planned End Date changed from 30 Jun 2023 to 31 May 2026.
    • 10 May 2024 Planned primary completion date changed from 31 Dec 2022 to 1 Oct 2025.
    • 12 Dec 2023 Results assessing characterise factors associated with early progression, presented at the 65th American Society of Hematology Annual Meeting and Exposition.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top